Dr. Mookerjee

Bijoyesh P. Mookerjee, MD

Contact Dr. Mookerjee

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma
  2. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
  3. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
  4. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer
  5. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial
  6. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
  7. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial
  8. Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms
  9. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): Results of a phase 3, open-label, randomised trial
  10. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial
  11. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
  12. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: A randomized Phase II study
  13. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III)
  14. Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
  15. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  16. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
  17. Adenovirus DNA polymerase is recognized by human CD8+T cells
  18. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy
  19. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy
  20. T Cell Repertoire Complexity Is Conserved after LLME Treatment of Donor Lymphocyte Infusions